N/A
Completed N=148
Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study
Source: ClinicalTrials.gov NCT02555930 ↗Enrolled (actual)
148
Serious AEs
0.0%
Results posted
Mar 2021
Primary outcomePrimary: Neuropathic Element of Pain Using the Doleur Neuropathique 4 Interview — 81; 67 Participants
Summary
This study aims to recruit a cohort of HIV patients with and without HIV-SN and to identify genetic risk factors for the development of HIV-SN and neuropathic pain. It also aims to more deeply phenotype the condition, using well validated questionnaires, and to identify any influence that early neurocognitive dysfunction may have on the reporting, diagnosis and treatment of neuropathic pain in the HIV population.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Neuropathic Element of Pain Using the Doleur Neuropathique 4 Interview |
81; 67 | — |
| SECONDARY Cognitive Function: Global T-score for Cogstate Computerised Cognitive Function Test Set |
48.09 | — |
| SECONDARY Conditioned Pain Modulation Efficiency |
0.78 | — |
Eligibility Criteria
Inclusion Criteria
- Aged 18 years or over
- HIV infection
Exclusion Criteria
- co-incident severe neurological disease
- co-incident severe psychiatric illness
- limited english language skills so as not able to conduct quantitative sensory testing
- pregnancy
- pain of greater than 3/10 on an NRS due to pathology other than HIV-SN
Data sourced from ClinicalTrials.gov (NCT02555930). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.